Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Terazosin in Amyotrophic Lateral Sclerosis
NCT07224269Phase 1Recruiting
- Sponsor
- University of Iowa
- Start
- Aug 2026
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing Terazosin with Placebo (2 arms). Primary endpoint: Change in ATP levels at 12 weeks. Started Aug 2026; status: recruiting.
02
Drugs
terazosin
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT07224269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07224269.